1,086 material Form 8-K filings that 883 companies we cover made with the SEC in July 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
SL Green reported a second-quarter 2025 net loss attributable to common stockholders of $11.1 million, or $0.16 per share, compared with a net loss of $2.2 million, or $0.04 per share, a year earlier, and FFO of $1.63 per share, down from $2.05. The company raised its 2025 FFO per share guidance to $5.65 to $5.95 while keeping its 2025 net income per share guidance at $1.27 to $1.57.
Q2 2025 net loss attributable to common stockholders was $11.1 million, or $0.16 per share, versus a net loss of $2.2 million, or $0.04 per share, in Q2 2024.
Q2 2025 FFO was $1.63 per share, down from $2.05 per share a year earlier; total revenues were $241.9 million versus $222.8 million.
2025 FFO per share guidance was revised to $5.65 to $5.95 from $5.25 to $5.55, an increase of $0.40 per share at the midpoint, while net income guidance of $1.27 to $1.57 per share was maintained.
Manhattan same-store office occupancy was 91.4% at June 30, 2025, and the company expects it to reach 93.2% by December 31, 2025.
Elevance Health reported second quarter 2025 operating revenue of $49.4 billion, up 14.3% from a year earlier, but diluted EPS fell to $7.72 from $9.85 and adjusted diluted EPS fell to $8.84 from $10.30. The company revised its full-year 2025 adjusted diluted EPS guidance to approximately $30.00 and projected GAAP diluted EPS of approximately $24.10, citing elevated medical cost trends in ACA and slower rate alignment in Medicaid. Shareholders face lower profit expectations even as sales grew.
Q2 2025 operating revenue $49.4 billion, up 14.3%; benefit expense ratio rose to 88.9% from 86.3% in the prior-year quarter
Q2 2025 diluted EPS $7.72 vs. $9.85 a year earlier; adjusted diluted EPS $8.84 vs. $10.30
2025 adjusted diluted EPS outlook revised to approximately $30.00; GAAP diluted EPS outlook approximately $24.10
Returned $2.0 billion to shareholders year-to-date; third quarter dividend of $1.71 per share payable September 25, 2025
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.